Our results in this cohort and our previous results6,7 suggest that genetic polymorphisms in TREML4, including in asymptomatic patients, influence mRNA expression in leukocytes and may regulate differently during the atherosclerosis progression stages, but not in symptomatic Atherosclerosis disease and post-MI. This evidence concerns the gene TREML4 and atherosclerosis.